CA2981158C - Process for the preparation of dicycloplatin - Google Patents
Process for the preparation of dicycloplatin Download PDFInfo
- Publication number
- CA2981158C CA2981158C CA2981158A CA2981158A CA2981158C CA 2981158 C CA2981158 C CA 2981158C CA 2981158 A CA2981158 A CA 2981158A CA 2981158 A CA2981158 A CA 2981158A CA 2981158 C CA2981158 C CA 2981158C
- Authority
- CA
- Canada
- Prior art keywords
- carboplatin
- dicycloplatin
- combining step
- solvent
- dicarboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IIJQICKYWPGJDT-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound N.N.[Pt+2].OC(=O)C1(C([O-])=O)CCC1.OC(=O)C1(C([O-])=O)CCC1 IIJQICKYWPGJDT-UHFFFAOYSA-L 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000008569 process Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 229960004562 carboplatin Drugs 0.000 claims description 66
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 50
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 25
- 229910001868 water Inorganic materials 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 4
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 4
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 4
- -1 Et0Ac Substances 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- 229940011051 isopropyl acetate Drugs 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims 9
- 244000126002 Ziziphus vulgaris Species 0.000 claims 1
- 238000013341 scale-up Methods 0.000 abstract description 5
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 57
- 239000000047 product Substances 0.000 description 44
- 238000002411 thermogravimetry Methods 0.000 description 19
- 238000000113 differential scanning calorimetry Methods 0.000 description 18
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000011521 glass Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 230000008570 general process Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- AENCTOAEVOLYHR-UHFFFAOYSA-N azanide cyclobutane-1,1-dicarboxylic acid platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.OC(=O)C1(C(O)=O)CCC1 AENCTOAEVOLYHR-UHFFFAOYSA-N 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- UMWYYMCOBYVEPY-UHFFFAOYSA-N azanide;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2] UMWYYMCOBYVEPY-UHFFFAOYSA-N 0.000 description 1
- SOUGLODYPBMACB-UHFFFAOYSA-N butane;hydrate Chemical compound O.CCCC SOUGLODYPBMACB-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-L cyclobutane-1,1-dicarboxylate(2-) Chemical compound [O-]C(=O)C1(C([O-])=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-L 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011863 silicon-based powder Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/025334 WO2016164040A1 (en) | 2015-04-10 | 2015-04-10 | Process for the preparation of dicycloplatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2981158A1 CA2981158A1 (en) | 2016-10-13 |
| CA2981158C true CA2981158C (en) | 2022-05-24 |
Family
ID=56895556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2981158A Active CA2981158C (en) | 2015-04-10 | 2015-04-10 | Process for the preparation of dicycloplatin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9447130B1 (OSRAM) |
| EP (1) | EP3280408B1 (OSRAM) |
| JP (1) | JP6925318B2 (OSRAM) |
| KR (1) | KR102432526B1 (OSRAM) |
| CN (1) | CN106132408B (OSRAM) |
| AU (1) | AU2015390714B2 (OSRAM) |
| CA (1) | CA2981158C (OSRAM) |
| DK (1) | DK3280408T3 (OSRAM) |
| ES (1) | ES2765648T3 (OSRAM) |
| IL (1) | IL254894B (OSRAM) |
| MX (1) | MX2017012985A (OSRAM) |
| RU (1) | RU2676269C1 (OSRAM) |
| WO (1) | WO2016164040A1 (OSRAM) |
| ZA (1) | ZA201706795B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016205782A1 (en) | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Composition containing carboplatin and use |
| WO2016205785A1 (en) | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
| AU2016284816B2 (en) | 2015-06-25 | 2021-10-07 | Syn-Nat Products Enterprise LLC | Pharmaceutical co-crystal composition and use thereof |
| CN106995467B (zh) * | 2017-05-03 | 2019-06-21 | 江苏大红鹰恒顺药业有限公司 | 一种微波催化合成双环铂的方法 |
| CN109053808B (zh) | 2017-06-21 | 2020-12-29 | 宋勤华 | 一种高纯度双环铂针状晶体的工业化制备方法 |
| MX2020005310A (es) * | 2017-11-21 | 2020-10-08 | Medoncare Pharmaceutical Co Ltd | Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo. |
| WO2019153220A1 (zh) * | 2018-02-09 | 2019-08-15 | 北京索普兴大医药研究有限公司 | 双环铂药物检测方法 |
| WO2019161526A1 (zh) * | 2018-02-22 | 2019-08-29 | 昆明贵研药业有限公司 | 一锅法制备双二羧酸二氨络铂(ii)衍生物的方法 |
| WO2018171371A2 (zh) * | 2018-02-22 | 2018-09-27 | 昆明贵研药业有限公司 | 一种双二羧酸二氨络铂(ii)衍生物的制备方法 |
| CN112262123B (zh) * | 2018-09-18 | 2023-12-15 | 昆明贵研药业有限公司 | 一种双二羧酸二氨络铂(ii)衍生物的纯化方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2106679C (en) * | 1991-03-23 | 1996-01-09 | Dae-Kee Kim | Novel platinum (ii) complex and processes for preparing the same |
| US5455270A (en) * | 1993-08-11 | 1995-10-03 | Bristol-Myers Squibb Co. | Stabilized solutions of platinum(II) antitumor agents |
| CN1121380C (zh) * | 2000-03-03 | 2003-09-17 | 北京兴大豪斯科技有限公司 | 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物 |
| EP1473298B1 (en) * | 2001-11-30 | 2009-05-13 | Jingzun Wang | Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions |
| JP4992089B2 (ja) * | 2005-03-18 | 2012-08-08 | 国立大学法人 東京大学 | ジアミノシクロヘキサン白金（ｉｉ）とブロック共重合体との配位化合物及びそれを含有する抗がん剤 |
| ATE430564T1 (de) * | 2005-03-28 | 2009-05-15 | Dabur Pharma Ltd | Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln |
| JP2009525273A (ja) * | 2006-01-30 | 2009-07-09 | プラットコー テクノロジーズ （プロプライエタリー） リミテッド | 白金（ｉｉ）錯体の調製 |
| CA2691047A1 (en) * | 2007-06-18 | 2008-12-24 | Platco Technologies (Proprietary) Limited | Platinum (iv) complexes |
-
2015
- 2015-04-10 ES ES15888686T patent/ES2765648T3/es active Active
- 2015-04-10 KR KR1020177032550A patent/KR102432526B1/ko active Active
- 2015-04-10 AU AU2015390714A patent/AU2015390714B2/en active Active
- 2015-04-10 EP EP15888686.1A patent/EP3280408B1/en active Active
- 2015-04-10 RU RU2017136078A patent/RU2676269C1/ru active
- 2015-04-10 CA CA2981158A patent/CA2981158C/en active Active
- 2015-04-10 MX MX2017012985A patent/MX2017012985A/es unknown
- 2015-04-10 WO PCT/US2015/025334 patent/WO2016164040A1/en not_active Ceased
- 2015-04-10 JP JP2018503718A patent/JP6925318B2/ja active Active
- 2015-04-10 DK DK15888686.1T patent/DK3280408T3/da active
- 2015-04-10 CN CN201580002750.5A patent/CN106132408B/zh active Active
-
2016
- 2016-04-12 US US15/097,071 patent/US9447130B1/en active Active
-
2017
- 2017-10-03 IL IL254894A patent/IL254894B/en active IP Right Grant
- 2017-10-09 ZA ZA2017/06795A patent/ZA201706795B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3280408A1 (en) | 2018-02-14 |
| BR112017021590A2 (pt) | 2018-07-03 |
| IL254894A0 (en) | 2017-12-31 |
| ZA201706795B (en) | 2019-02-27 |
| US9447130B1 (en) | 2016-09-20 |
| KR20170134737A (ko) | 2017-12-06 |
| CN106132408B (zh) | 2018-02-13 |
| CA2981158A1 (en) | 2016-10-13 |
| DK3280408T3 (da) | 2020-02-03 |
| IL254894B (en) | 2021-02-28 |
| JP2018510914A (ja) | 2018-04-19 |
| CN106132408A (zh) | 2016-11-16 |
| AU2015390714B2 (en) | 2021-02-04 |
| AU2015390714A1 (en) | 2017-10-26 |
| EP3280408B1 (en) | 2019-10-23 |
| US20160297842A1 (en) | 2016-10-13 |
| KR102432526B1 (ko) | 2022-08-12 |
| JP6925318B2 (ja) | 2021-08-25 |
| ES2765648T3 (es) | 2020-06-10 |
| RU2676269C1 (ru) | 2018-12-27 |
| WO2016164040A1 (en) | 2016-10-13 |
| MX2017012985A (es) | 2018-05-22 |
| EP3280408A4 (en) | 2018-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2981158C (en) | Process for the preparation of dicycloplatin | |
| Sowa et al. | Improving solubility of fisetin by cocrystallization | |
| He et al. | Polymorphism observed in dapsone–flavone cocrystals that present pronounced differences in solubility and stability | |
| CA3130247A1 (en) | Fgfr inhibitor compound in solid form and preparation method therefor | |
| Yu et al. | A supramolecular adduct of tegafur and syringic acid: the first tegafur-nutraceutical cocrystal with perfected in vitro and in vivo characteristics as well as synergized anticancer activities | |
| Liu et al. | sp2 CH⋯ Cl hydrogen bond in the conformational polymorphism of 4-chloro-phenylanthranilic acid | |
| JP7351061B2 (ja) | 縮合環ピリミジン系化合物の塩、結晶形並びにその製造方法と使用 | |
| Samie et al. | Orientation-dependent conformational polymorphs in two similar pyridine/pyrazine phenolic esters | |
| Kangara et al. | Conformational analysis and potential anticancer activity of [Pt (phen)(L1-κ S) 2] studied by single crystal X-ray diffraction and variable temperature 1 H and 195 Pt NMR spectroscopy | |
| CA2776361A1 (en) | Crystalline forms of substituted pyrazolopyrimidines | |
| Hu et al. | Solution growth and thermal treatment of crystals lead to two new forms of 2-((2, 6-dimethylphenyl) amino) benzoic acid | |
| CN105440082B (zh) | 一种洛铂晶体、制备方法及药物应用 | |
| Fernandes et al. | Studies on polymorph conversion in a new cyclodextrin inclusion compound | |
| JP2022525125A (ja) | ブレイアコニチンａのｅ結晶形及びその製造方法と応用 | |
| EP4177257B1 (en) | Succinate of octahydrothienoquinoline compound, and crystals thereof | |
| CN112142762A (zh) | 一种布鲁顿酪氨酸激酶抑制剂的晶体及其制备方法和用途 | |
| WO2017032349A1 (en) | Salts of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof | |
| CN105440083B (zh) | 一种洛铂晶体、制备方法及药物应用 | |
| US9365601B2 (en) | 1,2-cyclohexanediaminplatinum(II)-bis-(4-methylbenzenesulfonate) and the hydrates thereof | |
| BR112017021590B1 (pt) | Processo de preparação de dicicloplatina | |
| EP2771312B1 (en) | Agomelatine-urea complex and crystalline forms thereof | |
| JP2025128032A (ja) | ダプロデュスタットの共結晶 | |
| WO2015169269A1 (en) | Salts of 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide | |
| CN115073378A (zh) | (+)-1-(α-甲苄基)咪唑-5-羧酸乙酯的晶型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200326 |